Effect of CAFfeine on Cognition in Alzheimer's Disease

Prior treatment

• Patients who take forbidden treatment :
  • Psychotropic treatments introduced or modified \< 2 months before inclusion
  • Chronic use of CYP1A2 inducing or inhibiting drugs
  • All caffeine-containing specialties
  • Drugs that influence caffeine metabolism
  • Drugs that may interact with caffeine

Other illness

• Sleep disorders defined by severity and an impact on NPI-R; a patient fitted for OSA may be included if the device has been in use for 3 months and well tolerated (stable)
• Decompensated heart disease or severe rhythm disorder (excluding slow, treated and stable chronic atrial fibrillation)

Other

• Patients who refuse to adopt a low caffeine diet (eviction of tea, caffeinated sodas, chocolate in large quantities)
• Current major depressive episode according to DSM-5 criteria
• Another chronic pathology of the central nervous system
• Major anxiety according to the clinician (consistent with the corresponding nPI-R items that must indicate a severity \>2 and an impact \>3)
• Active smoking
• For childbearing women : pregnancy in progress or planned (A pregnancy test will be performed)

• Age ≥ 50 at screening
• Probable Alzheimer dementia according to the criteria of the National Institute on Aging-Alzheimer's Association; diagnosis must be supported by brain imaging (CT or MRI) and blood test (including ionogram, kidney and liver function, calcemia, CRP, TSH, B12 vitamins and folates) performed in routine care
• MMSE score ≥16
• Presence of an informant and caregiver, living with the patient
• IAChE and/or Memantine treatment non-compulsory ; If implemented it must be effective and stable for 2 months before the selection visit and must remain stable for the duration of the study